Search research articles
Contact Us
Filters
Showing results (211-220 of 282) with videos related to
Page
of 29
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 27, 2010
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer
Andrew J Armstrong, George J Netto, Michelle A Rudek, et al.
JNCI Cancer Spectrum
|
May 6, 2020
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel
Susan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
JCO Precision Oncology
|
April 30, 2026
Pertuzumab and Trastuzumab in Patients With <i>ERBB2/3</i>-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study
John K Chan, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Eugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Cancer Immunology, Immunotherapy : CII
|
November 6, 2009
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
James L Gulley, Philip M Arlen, Ravi A Madan, et al.
The Pharmacogenomics Journal
|
March 4, 2024
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)
Jai N Patel, Chen Jiang, Kouros Owzar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 23, 2024
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)
Rahul Aggarwal, Glenn Heller, David W Hillman, et al.
JCO Precision Oncology
|
November 6, 2020
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer
Andrew J Armstrong, Jun Luo, David M Nanus, et al.
JCO Precision Oncology
|
July 16, 2024
Palbociclib in Patients With Soft Tissue Sarcoma With <i>CDK4</i> Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study
Scott Schuetze, Michael Rothe, Pam K Mangat, et al.
The Lancet. Oncology
|
January 23, 2016
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
Andrew J Armstrong, Susan Halabi, Tim Eisen, et al.
Page
of 29
Search research articles
Search
Showing results (211-220 of 282) with videos related to
Sort By:
Page
of 29
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 27, 2010
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer
Andrew J Armstrong, George J Netto, Michelle A Rudek, et al.
JNCI Cancer Spectrum
|
May 6, 2020
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel
Susan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
JCO Precision Oncology
|
April 30, 2026
Pertuzumab and Trastuzumab in Patients With <i>ERBB2/3</i>-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study
John K Chan, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Eugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Cancer Immunology, Immunotherapy : CII
|
November 6, 2009
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
James L Gulley, Philip M Arlen, Ravi A Madan, et al.
The Pharmacogenomics Journal
|
March 4, 2024
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)
Jai N Patel, Chen Jiang, Kouros Owzar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 23, 2024
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)
Rahul Aggarwal, Glenn Heller, David W Hillman, et al.
JCO Precision Oncology
|
November 6, 2020
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer
Andrew J Armstrong, Jun Luo, David M Nanus, et al.
JCO Precision Oncology
|
July 16, 2024
Palbociclib in Patients With Soft Tissue Sarcoma With <i>CDK4</i> Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study
Scott Schuetze, Michael Rothe, Pam K Mangat, et al.
The Lancet. Oncology
|
January 23, 2016
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
Andrew J Armstrong, Susan Halabi, Tim Eisen, et al.
Page
of 29